hr-uconn-health-signature

Tannin A. Schmidt, Ph.D.

Associate Professor
Research Interests:
Associate Professor Tannin Schmidt’s research aims to understand the fundamental mechanisms and properties of lubricin, a critical lubricating protein found throughout the human body recently discovered to also have anti-inflammatory properties, at relevant biointerfaces and biomaterials (e.g. synovial joints and the ocular surface), and to apply that knowledge to the development of recombinant human lubricin-containing biotherapeutics and biomaterials.​
Address:
263 Farmington Avenue
University of Connecticut
Farmington, CT 06030
Office Phone:   860-679-8361
Education:
University of Toronto 

University of California, San Diego

University of California, San Diego

Rush University Medical Center, Chicago

B.A.Sc. 

M.S.

PhD

Postdoc

05/2000 

03/2002

06/2006

04/2008

Engineering Science 

Bioengineering

Bioengineering

Rheumatology & Biochemistry

Personal Statement

My research interests in bioengineering lie within biomaterials, biomechanics, bio tribology, and biochemistry. This is motivated by my combined training in engineering science, bioengineering and biochemistry, which provide me with a unique skill set and approach to biomedical engineering research. The overarching goal of my research program is to understand the fundamental mechanisms and properties of proteoglycan 4 (PRG4), also known as lubricin (a critical lubricating protein found throughout the human body, recently discovered to also have anti-inflammatory properties), at relevant bio interfaces and biomaterials. Moreover, to then apply that fundamental knowledge to the development of PRG4-containing bio therapeutics and biomaterials. I have been an active and productive independent researcher for 9+ years, with my laboratory (previously based at the University of Calgary) being internationally recognized for its work on PRG4. The initial focus of my research program has been orthopedic in nature, studying the relevance and application of PRG4 in osteoarthritis, but expanded to other organ systems and applications in the body including but not limited to the eye (e.g. dry eye, contact lenses), heart (inhibiting post-surgical pericardial adhesions), and biomaterials in general. Additionally, I have been successful in translating basic findings as a co-founder of Lubris BioPharma, a clinical stage startup company developing recombinant human PRG4 (rhPRG4)-based treatments for osteoarthritis, dry eye, and other diseases. I played a significant role in the development and characterization of rhPRG4, and have significant experience with the protein over the past 5 years. Collectively, my expertise and experience make me uniquely and ideally positioned to contribute to this project, specifically related to work on/with rhPRG4.